🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Nathalie Javidi‐Sharifi

Boston University

ORCID: 0000-0003-0702-9837

Also affiliated with Dana-Farber Cancer Institute

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies”.

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Blood Advances(2024)10.1182/bloodadvances.2024014633

N/A

0.420DataRank · unranked

9 citations

Danielle M. Brander, Yesid Alvarado, Catherine Diefenbach, Daniel Nathan Egan, Shira Dinner +14 more

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Blood Neoplasia(2025)10.1016/j.bneo.2025.100108

N/A

0.173DataRank · unranked

2 citations

Rachel J. Cook, Shira Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi‐Sharifi +9 more

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation

Hematological Oncology(2025)10.1002/hon.70064

N/A

0.165DataRank · unranked

2 citations

Matthew S. Davids, Nathalie Javidi‐Sharifi